Pharming balances expenses while awaiting FDA lactoferrin review
Dutch biotech group Pharming has played a successful balancing act with its finances in first half 2006, with both costs and expenses and losses totalling €8.1mm as awaits the US FDA's review of its GRAS filing for its human lactoferrin for functional...